Gastro-resistant controlled release oral dosage forms
This disclosure relates to gastro-resistant, controlled release dosage forms comprising Compound (I): (I), or a pharmaceutically acceptable salt and/or solvate thereof, the pharmacokinetic properties of these dosage forms, and the preparation of the same. The novel dosage forms disclosed herein are...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English |
Published |
13.06.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This disclosure relates to gastro-resistant, controlled release dosage forms comprising Compound (I): (I), or a pharmaceutically acceptable salt and/or solvate thereof, the pharmacokinetic properties of these dosage forms, and the preparation of the same. The novel dosage forms disclosed herein are useful in reducing the risk of QT prolongation in a subject and in treating a disorder in a subject in need thereof, e.g., a subject diagnosed with schizophrenia, for example, in treating the negative symptoms in a subject diagnosed with schizophrenia having the CYP2D6 EM genotype. |
---|---|
Bibliography: | Application Number: AU20180290287 |